Microsofts Responsible Tech Lead Outlines Approach to Humanizing Rapid AI Development Microsofts New Responsible Tech Lead Navigates Tension Between AI Speed and Trustworthy Development LongTerm Investment Focus Examining the Case for 20Year Stock Holdings SpaceX Launches Redesigned Starship in Successful PreIPO Test CBS Cancels The Late Show with Stephen Colbert Networks LateNight Strategy Shifts to Comics Unleashed Mistrals Chip Exploration Signals Infrastructure Push in Competitive AI Race Mid Penn Bancorp MPB Q1 2026 Earnings Missed Estimates Sharply as EPS Falls 51 Below Consensus UZD Q1 2026 Earnings EPS Surges Past Estimates by Nearly 90 as Digital Infrastructure Demand Accelerates YELP Q1 2026 Earnings EPS Beats Estimates Stock Rises MED Q1 2026 Earnings EPS Surpasses Estimates Amid Cost Management Efforts FET Q1 2026 Earnings Earnings Beat Partially Offset by Revenue Uncertainties EBF Q1 2026 Earnings EPS Misses Estimates Amid Operational Headwinds Driven Brands DRVN Jumps 3 as Stock Holds Key Support Zone Brinker International EAT Slips Amidst Trading Key Support Levels in Focus Arcelor Mittal MT Rallies 38 as Steel Sector Momentum Builds Weibo WB Edges Higher as Stock Holds Above Key Support Level SEI Investments SEIC Sees Modest Decline as Sector Rotation Continues Michael Price Advocates Contrarian Approach for Navigating Market Volatility Scinai Immunotherapeutics SCNI Q4 2023 Earnings NarrowerThanExpected Loss Amid Operational Adjustments Johnson Outdoors JOUT Stages a Modest Rebound Key Levels to Watch Lucid Motors Speculated as Potential Robotaxi Player From Fragile Promise to Identity The Decade That Reshaped American Soccers Financial Landscape Oppenheimer Initiates Coverage on Martin Marietta Materials with Perform Rating Huawei Unveils Logic Folding Chip Approach as Rivalry With Nvidia and Apple Intensifies Yaashvi Jewellers IPO Attracts 118x Subscription on Final Day of Bidding BJs Wholesale Club Delivers Q1 Fiscal 2026 Results Membership and Traffic Trends in Focus Eli Lillys NextGeneration Obesity Drug Retatrutide Achieves Primary Endpoint in Pivotal Trial